
  
    
      
        
        Coronary_NNP heart_NN disease_NN (_( CHD_NNP )_) is_VBZ the_DT leading_VBG cause_NN of_IN morbidity_NN and_CC mortality_NN in_IN
        developed_VBN countries_NNS ,_, and_CC identifying_VBG and_CC treating_VBG patients_NNS with_IN high_JJ cholesterol_NN has_VBZ an_DT
        essential_JJ role_NN in_IN the_DT prevention_NN of_IN CHD_NNP ._. Therapeutic_NNP lifestyle_NN changes_NNS are_VBP important_JJ for_IN
        general_JJ reduction_NN of_IN risk_NN overall_JJ ,_, but_CC patients_NNS who_WP are_VBP more_RBR likely_JJ to_TO develop_VB CHD_NNP ,_, or_CC who_WP
        have_VBP high_JJ cholesterol_NN ,_, should_MD be_VB treated_VBN with_IN statins_NNS ._. Statins_NNP inhibit_VB HMG-CoA_NNP reductase—a_NN
        key_JJ enzyme_NN in_IN the_DT cholesterol_NN synthesis_NN pathway_NN ._.
        Although_IN we_PRP know_VBP that_IN not_RB all_DT patients_NNS who_WP may_MD benefit_VB from_IN statins_NNS receive_VBP treatment_NN ,_,
        there_EX is_VBZ limited_VBN information_NN on_IN how_WRB patients_NNS are_VBP treated_VBN according_VBG to_TO their_PRP$ estimated_VBN risk_NN
        of_IN developing_VBG CHD_NNP ._. Patients_NNS may_MD be_VB classified_VBN as_IN at_IN low_JJ ,_, medium_NN ,_, or_CC high_JJ risk_NN of_IN developing_VBG
        CHD_NNP according_VBG to_TO the_DT presence_NN of_IN CHD_NNP ,_, some_DT other_JJ medical_JJ conditions_NNS (_( for_IN example_NN ,_,
        diabetes_NN )_) ,_, and_CC major_JJ risk_NN factors_NNS including_VBG cholesterol_NN level_NN ,_, smoking_NN ,_, lifestyle_NN ,_, and_CC
        family_NN history_NN ._. Jun_NNP Ma_NNP and_CC colleagues_NNS analyzed_VBD data_NNS from_IN the_DT National_NNP Ambulatory_NNP Medical_NNP
        Care_NNP Survey_NNP and_CC the_DT outpatient_NN department_NN component_NN of_IN the_DT National_NNP Hospital_NNP Ambulatory_NNP
        Medical_NNP Care_NNP Survey_NNP to_TO identify_VB changes_NNS in_IN treatment_NN from_IN 1993_CD to_TO 2002_CD ,_, and_CC to_TO identify_VB
        current_JJ clinical_JJ practice_NN ._. These_DT surveys_NNS have_VBP been_VBN validated_JJ against_IN other_JJ data_NNS sources_NNS ,_,
        and_CC used_VBD in_IN past_JJ research_NN on_IN cholesterol_NN management_NN ._.
        The_DT researchers_NNS found_VBD that_IN between_IN 1993_CD and_CC 2002_CD the_DT use_NN of_IN statins_NNS increased_VBN nearly_RB
        5_CD -_: fold_VB ,_, from_IN 9_CD %_NN to_TO 49_CD %_NN ,_, in_IN ambulatory_JJ visits_NNS by_IN patients_NNS with_IN high_JJ cholesterol_NN ,_, but_CC then_RB
        declined_VBD to_TO 36_CD %_NN in_IN 2002_CD ._. Overall_RB ,_, the_DT use_NN of_IN statins_NNS was_VBD three_CD times_NNS more_RBR likely_JJ in_IN 2001_CD
        and_CC 2002_CD than_IN in_IN 1995_CD and_CC 1996_CD ._. Patients_NNS at_IN high_JJ risk_NN of_IN CHD_NNP were_VBD more_RBR likely_JJ to_TO use_VB
        statins_NNS than_IN other_JJ patients_NNS ._. However_RB ,_, among_IN patients_NNS whose_WP$ visit_NN had_VBD a_DT reported_VBN high_JJ
        cholesterol_NN ,_, only_RB 50_CD %_NN of_IN patient_NN visits_NNS at_IN high_JJ risk_NN of_IN CHD_NNP and_CC 44_CD %_NN of_IN those_DT at_IN moderate_JJ
        risk_NN were_VBD prescribed_VBN statins_NNS in_IN 2002_CD ,_, well_RB below_IN the_DT recommendations_NNS of_IN current_JJ guidelines_NNS ._.
        Less_RBR than_IN half_PDT the_DT patient_NN visits_NNS that_WDT arguably_RB represent_VB optimal_NN opportunities_NNS for_IN
        counseling_NN services_NNS received_VBD counseling_VBG about_IN how_WRB they_PRP might_MD change_VB their_PRP$ lifestyle_NN ._. The_DT
        study_NN also_RB showed_VBD inequities_NNS in_IN use_NN of_IN statins_NNS for_IN patients_NNS with_IN different_JJ social_JJ and_CC
        clinical_JJ characteristics_NNS ,_, with_IN lower_JJR usage_NN in_IN younger_JJR patients_NNS ,_, females_NNS ,_, African-_NNP Americans_NNPS ,_,
        and_CC patients_NNS cared_VBD for_IN by_IN doctors_NNS who_WP are_VBP not_RB cardiologists_NNS ._.
        As_IN the_DT authors_NNS declare_VBP ,_, the_DT study_NN was_VBD funded_VBN by_IN a_DT maker_NN of_IN one_CD of_IN the_DT statins_NNS ,_, but_CC the_DT
        information_NN acquired_VBN is_VBZ of_IN general_JJ interest_NN ._. Persistent_NNP gaps_NNS in_IN statin_NN therapy_NN suggest_VBP a_DT
        need_NN for_IN improved_VBN identification_NN of_IN patients_NNS who_WP may_MD develop_VB CHD_NNP ,_, and_CC treatment_NN with_IN
        statins_NNS when_WRB indicated_VBD ,_, the_DT authors_NNS say_VBP ._. A_DT particular_JJ focus_NN should_MD be_VB patients_NNS who_WP are_VBP at_IN
        risk_NN of_IN developing_VBG CHD_NNP ._. Education_NNP should_MD be_VB aimed_VBN at_IN improving_VBG the_DT practice_NN of_IN
        physicians—above_NN all_DT ,_, those_DT who_WP are_VBP not_RB heart_NN specialists—so_NN that_IN they_PRP adhere_VB to_TO
        evidence-based_JJ medicine_NN and_CC published_VBN guidelines_NNS for_IN cardiovascular_JJ risk_NN reduction_NN ._. In_IN an_DT
        accompanying_VBG Perspective_NNP (_( DOI_NNP :_: 10_CD ._. 1371_CD /_NN journal_NN ._. pmed_JJ ._. 0020131_CD )_) ,_, Fiona_NNP Turnbull_NNP from_IN the_DT
        George_NNP Institute_NNP for_IN International_NNP Health_NNP says_VBZ that_IN physicians_NNS need_VBP to_TO move_VB away_RB from_IN
        making_VBG treatment_NN decisions_NNS based_VBN on_IN single_JJ risk_NN factors_NNS and_CC instead_RB use_VB an_DT approach_NN based_VBN
        on_IN absolute_JJ risk_NN ._. “ An_DT understanding_NN of_IN the_DT concept_NN of_IN ‘ absolute_JJ risk_NN’ —_NN the_DT probability_NN of_IN a_DT
        patient_NN developing_VBG a_DT cardiovascular_JJ event_NN over_IN a_DT specified_VBN time_NN period—is_NNS crucial_JJ ,_,” she_PRP
        says_VBZ ._.
      
    
  
